Dr. Reddy’s Laboratories rolls out Regadenoson Injection in US

Indian pharma company Dr. Reddy’s Laboratories said that it has launched Regadenoson Injection 0.4 mg/5 mL in the US market.

Approved by the US Food and Drug Administration (FDA), Regadenoson Injection is a generic therapeutic equivalent of Lexiscan (Regadenoson) injection of Astellas US.

It is a pharmacologic stress agent for radionuclide myocardial perfusion imaging (MPI).

Dr. Reddy’s Laboratories’ Regadenoson Injection is available as single-dose pre-filled syringes, 0.4 mg/5 mL (0.08 mg/mL).